Skip to main content
SpringerLink
Log in

Sudden Cardiac Death Unresponsive to Implantable Defibrillator Therapy: An Urgent Target for Clinicians, Industry and Government

  • Editorial
  • Published:
Journal of Interventional Cardiac Electrophysiology Aims and scope Submit manuscript

Abstract

A major expansion in utilization of implantable cardioverter-defibrillators (ICDs) is anticipated based on the results of randomized clinical trials (RCT) that demonstrate increased survival in a sizable population of patients with reduced left ventricular function. However, if RCT accurately reflect clinical practice, then a substantial proportion of patients will die suddenly despite ICD implantation. ICD-unresponsive sudden cardiac death (SCD) has been recognized since the initial ICD experience. Yet, despite 25 years of technical advances, the frequency of ICD-unresponsive SCD has not declined. Pooled analysis of RCT indicates a crude rate of ICD-unresponsive SCD of 5%. This may not cause alarm in an average practice, but it comprises about 30% of cardiac deaths. Meta-analyses of RCT show that ICD therapy is associated with a relative risk reduction of SCD of approximately 60%, far less than the greater than 90% efficacy that many expect. The suboptimal performance of ICD therapy accounts for the failure of some RCT to achieve statistically significant effects on survival. The number of patients with ICD-unresponsive SCD is highly correlated with the number of cardiac deaths among control patients as well as ICD recipients. Otherwise, no definite patterns have emerged that clearly distinguish this mode of demise from other modes of cardiac death. Retrospective post-hoc analyses have not revealed distinguishing characteristics of patients with ICD-unresponsive SCD with respect to clinical variables, pre-terminal symptoms or to the setting of the terminal event. Despite advanced storage capabilities of implanted devices, almost no information has become available from RCT regarding the terminal rhythm or the response of the ICD. These observations have implications for clinical management and research.

Candidates for ICD implantation based on RCT should be accurately informed about the residual risk of SCD. Investigators seeking to identify populations likely to benefit from ICD therapy based on SCD incidence should recognize that a significant fraction may not respond to ICD therapy. Reducing the incidence of ICD-unresponsive SCD would substantially improve survival and cost-effectiveness related to ICD therapy. Close cooperation between clinicians, investigators and representatives of industry and government is urgently needed to develop strategies to identify patients prone to ICD-unresponsive SCD, to determine its mechanisms and to develop methods of prevention and treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Warner KG, Halpin DP, Berul CI, Payne DD. Placement of a permanent epicardial pacemaker in children using a subcostal approach. Ann Thorac Surg 1999;68:173–175.

    Article  PubMed  CAS  Google Scholar 

  2. Mirowski M, Reid PR, Winkle RA, Mower MM, Watkins L Jr, Stinson EB, Griffith LS, Kallman CH, Weisfeldt ML. Mortality in patients with implanted automatic defibrillators. Ann Intern Med1983;98:585–588.

    PubMed  CAS  Google Scholar 

  3. Echt DS, Armstrong K, Schmidt P, Oyer PE, Stinson EB, Winkle RA. Clinical experience, complications, and survival in 70 patients with the automatic implantablecardioverter/defibrillator. Circulation 1985;71:289–296.

    PubMed  CAS  Google Scholar 

  4. Fogoros RN, Fiedler SB, Elson JJ. The automatic implantable cardioverter-defibrillator indrug-refractory ventricular tachyarrhythmias. Ann Intern Med 1987;107(5): 635–641.

    PubMed  CAS  Google Scholar 

  5. Kelly PA, Cannom DS, Garan H, Mirabal GS, Harthorne JW, Hurvitz RJ, Vlahakes GJ, Jacobs ML, Ilvento JP, Buckley MJ, Ruskin JN. The automatic implantable cardioverter-defibrillator: Efficacy, complications and survival in patients with malignant ventricular arrhythmias. J Am Coll Cardiol 1988;11:1278–1286.

    Article  PubMed  CAS  Google Scholar 

  6. Winkle RA, Mead RH, Ruder MA, et al. Long-term outcome with the automatic implantablecardioverter-defibrillator. J Am Coll Cardiol 1989;13:1353–1361.

    PubMed  CAS  Google Scholar 

  7. Fogoros RN, Elson JJ, Bonnet CA. Actuarial incidence and pattern of occurrence of shocks followingimplantation of the automatic implantable cardioverter defibrillator. Pacing Clin Electrophysiol 1989;12:1465–1473.

    PubMed  CAS  Google Scholar 

  8. Levine JH, Mellits ED, Baumgardner RA, Baumgardner RA, {Veltri EP}, {Mower M}, {Grunwald L}, {Guarnieri T}, {Aarons D}, Griffith LS. Predictors of first discharge and subsequent survivalin patients with automatic implantable cardioverter-defibrillators. Circulation1991;84:558–566.

    PubMed  CAS  Google Scholar 

  9. Newman D, Sauve MJ, Herre J, Langberg JJ, Lee MA, Titus C, Franklin J, Scheinman MM, Griffin JC. Survival after implantation of the cardioverter defibrillator. Am J Cardiol 1992;69:899–903.

    Google Scholar 

  10. Powell AC, Fuchs T, Finkelstein DM, Garan H, Cannom DS, McGovern BA, Kelly E, Vlahakes GJ, Torchiana DF, Ruskin JN. Influence of implantable cardioverter-defibrillators on the long-termprognosis of survivors of out-of-hospital cardiac arrest. Circulation 1993;88:1083–1092.

    Google Scholar 

  11. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patientsresuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 1997;337(22):1576–1583.

  12. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, Sanders WE, Schaechter A, Levine JH. Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patientswith nonischemic dilated cardiomyopathy. N Engl J Med 2004 May 20;350:2151–2158.

    Article  CAS  Google Scholar 

  13. Kuck KH, Cappato R, Siebels J, Rueppel R. CASH Investigators. Randomized comparison ofantiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiacarrest—The Cardiac Arrest Study Hamburg (CASH). Circulation 2000, 1915;102:748–754.

    Google Scholar 

  14. Connolly S, Gent M, Roberts R, Dorian P, Roy D, Sheldon R, Mitchell L, Green M, Klein G, O'Brien B, CIDS I. Canadian implantable defibrillator study (CIDS)—A randomized trial of the implantablecardioverter defibrillator against amiodarone. Circulation 2000;101:1297–1302.

    PubMed  CAS  Google Scholar 

  15. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M. Improved survival with an implanted defibrillator in patients withcoronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996;335:1933–1940.

    Article  PubMed  CAS  Google Scholar 

  16. Bigger JT Jr, Di Marco JP, Rottman JN. Prophylactic use of implanted cardiac defibrillators inpatients at high risk for ventricular arrhythmias after coronary-artery bypass graftsurgery—reply. N Engl J Med 1998;338:1228–1228.

    Google Scholar 

  17. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylacticimplantation of a defibrillator in patients with myocardial infarction and reduced ejectionfraction. N Engl J Med 2002;346:877–883.

    Article  PubMed  Google Scholar 

  18. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, Fain E, Gent M, Connolly SJ. DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acutemyocardial infarction. N Engl J Med 2004;351:2481–2488.

    Article  PubMed  CAS  Google Scholar 

  19. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH. Sudden Cardiac Death in Heart Failure Trial (SCD-He FT) Investigators. Amiodarone or animplantable cardioverter-defibrillator for congestive heart failure. N Engl J Med2005;352(3):225–237.

    Article  PubMed  CAS  Google Scholar 

  20. Ezekowitz JA, Armstrong PW, McAlister FA. Implantable cardioverter defibrillators in primary andsecondary prevention: A systematic review of randomized, controlled trials. Ann Intern Med 2003;138(6):445–452.

    PubMed  Google Scholar 

  21. Lee DS, Green LD, Liu PP, Dorian P, Newman DM, Grant FC, Tu JV, Alter DA. Effectiveness ofimplantable defibrillators for preventing arrhythmic events and death—A meta-analysis. J Am Coll Cardiol 2003;41:1573–1582.

    PubMed  Google Scholar 

  22. Al-Khatib SM, Sanders GD, Mark DB, Lee KL, Bardy GH, Bigger JT, Buxton AE, Connolly S, Kadish A, Moss A, Feldman AM, Ellenbogen KA, Singh S, Califf RM. Expert panel participating in a Duke Clinical Research Institute-sponsored conference. Implantable cardioverter defibrillators andcardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trialevidence through 2004. Am Heart J 2005:1020–1034.

  23. Packer DL, Bernstein R, Wood F, Boehmer J, Carlson M, Frantz RP, Mitchell LB, McNulty SE, Poole J, Rogers J, Anderson J, Walsh MN, Lee KL, Bardy GH, Boineau R, Domanski M. Impact of amiodaroneversus implantable cardioverter defibrillator therapy on the mode of death in congestive heartfailure patients in the SCDHe FT trial (abstr). Heart Rhythm 2005;2:S39.

    Google Scholar 

  24. Gornick CC, Hauser RG, Almquist AK, Maron BJ. Unpredictable implantable cardioverter-defibrillatorpulse generator failure due to electrical overstress causing sudden death in a young high-riskpatient with hypertrophic cardiomyopathy. Heart Rhythm 2005;2:681–683.

    Article  PubMed  Google Scholar 

  25. Steinbrook R. The controversy over Guidant's implantable defibrillators. N Engl J Med2005;353(3):221–224.

    Article  PubMed  CAS  Google Scholar 

  26. Mitchell LB, Pineda EA, Titus JL, Bartosch PM, Benditt DG. Sudden death in patients withimplantable cardioverter defibrillators: The importance of post-shock electromechanical dissociation. J Am Coll Cardiol 2002;39:1323–1328.

    PubMed  Google Scholar 

  27. AVID Investigators. Causes of death in the Antiarrhythmics Versus Implantable Defibrillators(AVID) Trial. J Am Coll Cardiol 1999;34:1552–1559.

    Google Scholar 

  28. Bigger JT Jr, Whang W, Rottman JN, Kleiger RE, Gottlieb CD, Namerow PB, Steinman RC, Estes NA 3rd.Mechanisms of death in the CABG Patch trial: A randomized trial of implantable cardiacdefibrillator prophylaxis in patients at high risk of death after coronary artery bypass graftsurgery. Circulation 1999;99:1416–1621.

    PubMed  Google Scholar 

  29. Greenberg H, Case RB, Moss AJ, Brown MW, Carroll ER, Andrews ML. MADIT-II Investigators. Analysisof mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol 2004;43:1459–1465.

    PubMed  Google Scholar 

  30. Heart Rhythm Society, Patients and the Public, Treatments, Implanted Cardiac Defibrillators:http://www.hrspatients.org/patients/treatments/cardiac_defibrillators/default.asp (lastaccessed August 14, 2005).

  31. Heart Rhythm Society, Patients and the Public, Treatments, Implanted Cardiac Defibrillators, Common Questions about ICDs:http://www.hrspatients.org/patients/treatments/cardiac_defibrillators/common_questions.asp (last accessed August 14, 2005).

  32. Gorsett A. Urgent Medical Device Safety Information & Corrective Action. Guidant “Dear Doctor”Letter, June 17, 2005.

  33. Salukhe TV, Dimopoulos K, Sutton R, Coats AJ, Piepoli M, Francis DP. Life-years gained fromdefibrillator implantation: Markedly nonlinear increase during 3 years of follow-up and itsimplications. Circulation 2004;109(15):1848–1853.

    Article  PubMed  Google Scholar 

  34. Owens DK, Sanders GD, Heidenreich PA, McDonald KM, Hlatky MA. Effect of risk stratification on cost-effectivenessof the implantable cardioverter defibrillator. Am Heart J 2002;144:440–448.

    Article  PubMed  Google Scholar 

  35. Sudden Cardiac Death in Heart Failure Trial (SCD-He FT) Investigators. Operations Manual1998;8:1–3.1

    Google Scholar 

  36. Saksena S. Prophylactic ICDs: Can (and will) the medical marketplace decide their role? J Interv Card Electrophysiol 2005;12(3):175–176.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Marshfield Clinic, Marshfield, WI

    Kelley P. Anderson M.D.

  2. Department of Cardiology 2D2, Marshfield Clinic, 1000 North Oak Avenue, Marshfield, WI, 54449-5777

    Kelley P. Anderson M.D.

Authors
  1. Kelley P. Anderson M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kelley P. Anderson M.D..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Anderson, K.P. Sudden Cardiac Death Unresponsive to Implantable Defibrillator Therapy: An Urgent Target for Clinicians, Industry and Government. J Interv Card Electrophysiol 14, 71–78 (2005). https://doi.org/10.1007/s10840-005-4547-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10840-005-4547-9

Keywords

Search

Navigation